Evidence map›Paper›PMID 41828052›Full record

ReviewDiagnostics (Basel, Switzerland)2026

Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management.

Marcella Buono, Luigi Schiavone, Sighelgaita Rizzo, Lanfranco Aquilino Musto, Gianluca Gatta, Lucia Pilati, Francesca Caumo

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marcella BuonoDepartment of Interventional and Emergency Radiology, San Giuseppe Moscati Hospital, 83100 Avellino, Italy.
Luigi SchiavoneRadiology Unit, Department of Precision Medicine, University of Campania "L. Vanvitelli", Piazza Luigi Miraglia, 80138 Naples, Italy.
Sighelgaita RizzoDepartment of Interventional and Emergency Radiology, San Giuseppe Moscati Hospital, 83100 Avellino, Italy.
Lanfranco Aquilino MustoDepartment of Interventional and Emergency Radiology, San Giuseppe Moscati Hospital, 83100 Avellino, Italy.
Gianluca GattaRadiology Unit, Department of Precision Medicine, University of Campania "L. Vanvitelli", Piazza Luigi Miraglia, 80138 Naples, Italy.ORCID 0000-0003-0874-8294
Lucia PilatiUnit of Breast Radiology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata, 35128 Padua, Italy.ORCID 0009-0007-7767-9372
Francesca CaumoUnit of Breast Radiology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata, 35128 Padua, Italy.ORCID 0000-0002-9457-5176

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread implementation of population-based mammographic screening has markedly increased the detection of ductal carcinoma in situ (DCIS), without a proportional reduction in breast cancer-specific mortality. This divergence has intensified concerns regarding overdiagnosis and overtreatment and has prompted increasing interest in treatment de-escalation and active surveillance strategies. Breast imaging remains indispensable for DCIS detection, extent assessment, and longitudinal monitoring. However, although imaging features correlate with histopathologic risk factors at the population level, their ability to predict individual biological progression is inherently probabilistic and limited. Overinterpretation of imaging phenotypes as surrogates of invasive destiny risks inappropriate reassurance or unjustified therapeutic escalation, particularly in the context of high-sensitivity modalities that may overestimate disease extent or trigger additional interventions without proven outcome benefits. This review examines the modality-specific roles of mammography, ultrasound, breast magnetic resonance imaging (MRI), contrast-enhanced mammography (CEM), and emerging artificial intelligence (AI) approaches within contemporary DCIS management, with particular attention to their implementation in active surveillance trials such as LORIS, COMET, LORD, and LORETTA. Across modalities, imaging primarily reflects lesion morphology, spatial distribution, and vascular behaviour, and functions most reliably as a risk-filtering and safety-gating instrument aimed at excluding radiologically unsafe scenarios, including occult invasion, underestimated disease extent, or imaging evolution incompatible with continued observation. By delineating both the capabilities and the epistemological limits of imaging, this review proposes a structured clinical decision framework in which imaging supports-but does not independently determine-risk-adapted management. Disciplined integration of imaging into multidisciplinary decision-making is essential to enable safe de-escalation, prevent false reassurance, and align DCIS care with patient-centred and value-based principles.

Indexed as

active surveillancebreast magnetic resonance imagingcontrast-enhanced mammographyductal carcinoma in situ (DCIS)imaging-based risk stratificationmammographytreatment de-escalationultrasound

Identifiers

PMID41828052
PMCPMC12985009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.